Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Side Effects of Alzheimer's Disease Treatment

Author(s): Тamara Lazarević-Pašti*

Volume 30, Issue 24, 2023

Published on: 23 January, 2023

Page: [2705 - 2709] Pages: 5

DOI: 10.2174/0929867330666230112160522

Price: $65

« Previous Next »
[1]
World Health Organization. Dementia. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
[2]
Alzheimer’s News Today. Alzheimer’s Disease Statistics. Available from: https://alzheimersnewstoday.com/alzheimers-disease-statistics/
[3]
Alzheimer’s Disease International. World Alzheimer Report., 2018. Available from: https://www.alzint.org/u/World AlzheimerRe-port2018.pdf
[4]
Revett, T.; Baker, G.; Jhamandas, J.; Kar, S. Glutamate system, amyloid β peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. J. Psychiatry Neurosci., 2013, 38(1), 6-23.
[http://dx.doi.org/10.1503/jpn.110190] [PMID: 22894822]
[5]
Lazarevic-Pasti, T.; Leskovac, A.; Momic, T.; Petrovic, S.; Vasic, V. Modulators of acetylcholinesterase activity: from Alzheimer’s disease to anti-cancer drugs. Curr. Med. Chem., 2017, 24(30), 3283-3309.
[PMID: 28685687]
[6]
Mitić, M.; Lazarević-Pašti, T. Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression? Expert Opin. Drug Metab. Toxicol., 2021, 17(7), 841-856.
[http://dx.doi.org/10.1080/17425255.2021.1931681] [PMID: 33999717]
[7]
Colović, M.B.; Krstić, D.Z.; Lazarević-Pašti, T.D.; Bondžić, A.M.; Vasić, V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol., 2013, 11(3), 315-335.
[http://dx.doi.org/10.2174/1570159X11311030006] [PMID: 24179466]
[8]
Parsons, C.G.; Danysz, W.; Dekundy, A.; Pulte, I. Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox. Res., 2013, 24(3), 358-369.
[http://dx.doi.org/10.1007/s12640-013-9398-z] [PMID: 23657927]
[9]
Danysz, W.; Parsons, C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: Preclinical evidence. Int. J. Geriatr. Psychiatry, 2003, 18(Suppl. 1), S23-S32.
[http://dx.doi.org/10.1002/gps.938] [PMID: 12973747]
[10]
Ajoolabady, A.; Lindholm, D.; Ren, J.; Pratico, D. ER stress and UPR in Alzheimer’s disease: Mechanisms, pathogenesis, treatments. Cell Death Dis., 2022, 13(8), 706.
[http://dx.doi.org/10.1038/s41419-022-05153-5] [PMID: 35970828]
[11]
Farhan, M.; Awesh, Y.K. Recent Trends in Nano-particulate carriers for the diagnosis and treatment of Alzheimer’s disease. CNS Neurol. Disord. Drug Targets, 2022.
[12]
Hansen, R.A.; Gartlehner, G.; Webb, A.P.; Morgan, L.C.; Moore, C.G.; Jonas, D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin. Interv. Aging, 2008, 3(2), 211-225.
[PMID: 18686744]
[13]
Harrison, V.; Mackenzie Ross, S. Anxiety and depression following cumulative low-level exposure to organophosphate pesticides. Environ. Res., 2016, 151, 528-536.
[http://dx.doi.org/10.1016/j.envres.2016.08.020] [PMID: 27575752]
[14]
Sanne, B.; Mykletun, A.; Dahl, A.A.; Moen, B.E.; Tell, G.S. Occupational differences in levels of anxiety and depression: the Hordaland Health Study. J. Occup. Environ. Med., 2003, 45(6), 628-638.
[http://dx.doi.org/10.1097/01.jom.0000069239.06498.2f] [PMID: 12802216]
[15]
Yang, M.; Li, C.; Zhang, Y.; Ren, J. Interrelationship between Alzheimer’s disease and cardiac dysfunction: the brain–heart continuum? Acta Biochim. Biophys. Sin. (Shanghai), 2020, 52(1), 1-8.
[http://dx.doi.org/10.1093/abbs/gmz115] [PMID: 31897470]
[16]
Lozupone, M.; La Montagna, M.; D’Urso, F.; Piccininni, C.; Sardone, R.; Dibello, V.; Giannelli, G.; Solfrizzi, V.; Greco, A.; Daniele, A.; Quaranta, N.; Seripa, D.; Bellomo, A.; Logroscino, G.; Panza, F. Pharmacotherapy for the treatment of depression in patients with Alzheimer’s disease: a treatment-resistant depressive disorder. Expert Opin. Pharmacother., 2018, 19(8), 823-842.
[http://dx.doi.org/10.1080/14656566.2018.1471136] [PMID: 29726758]
[17]
Smalheiser, N.R. Ketamine: A neglected therapy for Alzheimer disease. Front. Aging Neurosci., 2019, 11, 186.
[http://dx.doi.org/10.3389/fnagi.2019.00186] [PMID: 31396078]
[18]
Kishi, T.; Matsunaga, S.; Oya, K.; Nomura, I.; Ikuta, T.; Iwata, N. Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis. J. Alzheimers Dis., 2017, 60(2), 401-425.
[http://dx.doi.org/10.3233/JAD-170424] [PMID: 28922160]
[19]
McShane, R.; Westby, M.J.; Roberts, E.; Minakaran, N.; Schneider, L.; Farrimond, L.E.; Maayan, N.; Ware, J.; Debarros, J. Memantine for dementia. Cochrane Database Syst. Rev., 2019, 3, CD003154.
[PMID: 30891742]
[20]
Panza, F.; Lozupone, M.; Logroscino, G.; Imbimbo, B.P. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat. Rev. Neurol., 2019, 15(2), 73-88.
[http://dx.doi.org/10.1038/s41582-018-0116-6] [PMID: 30610216]
[21]
Mullard, A. Anti-amyloid failures stack up as Alzheimer antibody flops. Nat. Rev. Drug Discov., 2019.
[http://dx.doi.org/10.1038/d41573-019-00064-1] [PMID: 31048802]
[22]
Panza, F.; Lozupone, M.; Bellomo, A.; Imbimbo, B.P. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients? Ageing Res. Rev., 2019, 55, 100948.
[http://dx.doi.org/10.1016/j.arr.2019.100948] [PMID: 31454563]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy